What is Trellis Bioscience?
Trellis Bioscience is dedicated to the discovery and development of human monoclonal antibodies (mAbs) targeting critical areas such as infectious diseases and oncology. The company leverages its proprietary CellSpot platform to advance a pipeline of potential treatments, including TRL1068, which aims to combat challenging conditions like prosthetic joint infections and various viral infections. Their strategic focus is on enhancing therapeutic options for patients and healthcare providers, with an emphasis on improving treatment outcomes and reducing the need for invasive procedures. The company's commitment to clinical evaluation and technological innovation positions it as a key player in the pharmaceutical industry's pursuit of advanced medical solutions.
How much funding has Trellis Bioscience raised?
Trellis Bioscience has raised a total of $28.5M across 3 funding rounds:
Series A
$3.4M
Series B
$10M
Private Equity
$6.1M
Series A (2004): $3.4M, investors not publicly disclosed
Series B (2007): $10M, investors not publicly disclosed
Private Equity (2026): $6.1M, investors not publicly disclosed
What's next for Trellis Bioscience?
The substantial enterprise-level funding and recent strategic investment indicate a pivotal growth phase for Trellis Bioscience. This capital infusion is expected to accelerate the advancement of their product pipeline, particularly TRL1068, through further clinical trials and development stages. The company's focus on infectious diseases and cancer, coupled with its innovative antibody discovery platform, suggests a strategic expansion into new therapeutic frontiers. Future developments will likely involve scaling manufacturing capabilities, forging strategic partnerships, and potentially seeking regulatory approvals to bring their novel antibody-based therapies to market, addressing unmet medical needs in critical disease areas.
See full Trellis Bioscience company page
